GLUTATHIONE ( DrugBank: Glutathione )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病5
299嚢胞性線維症7

6. パーキンソン病


臨床試験数 : 2,298 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05266417
(ClinicalTrials.gov)
February 7, 202223/2/2022Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's DiseaseA Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of Intranasal Insulin and Glutathione as an Add-On Therapy in Subjects With Parkinson's Disease (NOSE-PD)Parkinson DiseaseDrug: INS-GSH;Drug: Matched PlacebosGateway Institute for Brain ResearchNULLRecruiting30 Years85 YearsAll56Phase 2United States
2NCT02424708
(ClinicalTrials.gov)
April 201515/4/2015Phase IIb Study of Intranasal Glutathione in Parkinson's DiseasePhase IIb Study of Intranasal Glutathione in Parkinson's DiseaseParkinson's DiseaseDrug: Reduced Glutathione 100mg;Drug: Reduced Glutathione 200mg;Drug: PlaceboBastyr UniversityMichael J. Fox Foundation for Parkinson's ResearchCompleted21 YearsN/ABoth45Phase 2United States
3NCT02324426
(ClinicalTrials.gov)
December 20144/12/2014CNS Uptake of Intranasal GlutathioneCentral Nervous System Uptake of Intranasal Glutathione in Parkinson's DiseaseParkinson's DiseaseDrug: Reduced GlutathioneUniversity of WashingtonMichael J. Fox Foundation for Parkinson's ResearchCompleted18 YearsN/ABoth15Phase 1United States
4NCT01398748
(ClinicalTrials.gov)
July 201219/7/2011Intranasal Glutathione in Parkinson's DiseaseA Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's DiseaseParkinson's Disease (PD)Drug: Intranasal glutathione - (in)GSH;Drug: Saline Intranasal DeliveryBastyr UniversityNational Center for Complementary and Integrative Health (NCCIH)Completed21 Years100 YearsAll34Phase 1United States
5NCT01177319
(ClinicalTrials.gov)
September 20035/8/2010Glutathione (GSH) In The Treatment of Parkinson's DiseaseGlutathione (GSH) In The Treatment of Parkinson's DiseaseParkinson's DiseaseDrug: GlutathioneUniversity of South FloridaWellness Health & Pharmaceuticals, Inc.Completed18 YearsN/ABoth20Phase 2United States

299. 嚢胞性線維症


臨床試験数 : 1,696 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03020719
(ClinicalTrials.gov)
June 14, 201711/1/2017The Role of Oral Glutathione on Growth Parameters in Children With Cystic FibrosisA Multi Center Placebo Controlled Double Blind Randomized Study Evaluating the Role of Oral Glutathione on Growth Parameters in Children With Cystic FibrosisCystic FibrosisDrug: Oral Glutathione;Drug: PlaceboUniversity of MinnesotaCystic Fibrosis FoundationCompleted2 Years11 YearsAll60Phase 2United States
2EUCTR2013-005481-19-DK
(EUCTR)
27/05/201427/05/2014High Dose Antioxidant Treatment for Patients with Cystic FibrosisHigh Dose Antioxidant Treatment for Patients with Cystic Fibrosis Cystic Fibrosis
MedDRA version: 17.0;Level: LLT;Classification code 10068288;Term: Cystic fibrosis pulmonary exacerbation;System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Mucolysin
INN or Proposed INN: ACETYLCYSTEINE
Other descriptive name: ACETYLCYSTEINE
Trade Name: Mucomyst
INN or Proposed INN: ACETYLCYSTEINE
Other descriptive name: ACETYLCYSTEINE
Trade Name: ACC
INN or Proposed INN: ACETYLCYSTEINE
Other descriptive name: ACETYLCYSTEINE
Trade Name: Tad
INN or Proposed INN: GLUTATHIONE
Other descriptive name: GLUTATHIONE SODIUM
Aarhus University HospitalNULLNot RecruitingFemale: yes
Male: yes
Phase 2Denmark
3NCT02029521
(ClinicalTrials.gov)
March 201130/12/2013Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis PatientsSupplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis for Growth FailureCystic FibrosisDietary Supplement: Oral reduced l-glutathione;Dietary Supplement: PlaceboClark BishopNULLCompleted18 Months10 YearsAll47N/AItaly
4NCT01450267
(ClinicalTrials.gov)
June 201030/9/2011Inhaled Glutathione (GSH) Versus Placebo in Cystic FibrosisRandomized, Single Blind, Controlled Trial of Inhaled Glutathione Versus Placebo in Patients With Cystic FibrosisCystic FibrosisDrug: Inhaled Reduced Glutathione;Drug: Physiological solutionSerafino A. MarsicoFederico II UniversityRecruiting6 Years45 YearsBoth150Phase 3Italy
5EUCTR2008-005080-33-IT
(EUCTR)
05/02/200919/01/2009RANDOMIZED, SINGLE BLIND, CONTROLLED TRIAL OF INHALED GLUTATHIONE VERSUS PLACEBO IN PATIENTS WITH CYSTIC FIBROSIS. - INHALED GSH VS PLACEBO IN CYSTIC FIBROSISRANDOMIZED, SINGLE BLIND, CONTROLLED TRIAL OF INHALED GLUTATHIONE VERSUS PLACEBO IN PATIENTS WITH CYSTIC FIBROSIS. - INHALED GSH VS PLACEBO IN CYSTIC FIBROSIS Cystic fibrosis.
MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung
Trade Name: TAD 600
INN or Proposed INN: Glutathione
AZIENDA OSPEDALIERA VINCENZO MONALDI DI NAPOLINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
6NCT00506688
(ClinicalTrials.gov)
July 200724/7/2007Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis PatientsRandomized, Placebo-controlled, Double-blinded Study to Investigate the Efficacy and Safety of a 24-week Inhalation Treatment With Glutathione in Cystic Fibrosis PatientsCystic FibrosisDrug: reduced glutathione sodium salt;Drug: 0.9% normal saline (control)Mukoviszidose Institut gGmbHCystic Fibrosis Foundation TherapeuticsCompleted8 YearsN/ABoth153Phase 2Germany
7EUCTR2005-003870-88-DE
(EUCTR)
20/10/200628/08/2006Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-week inhalation treatment with glutathione in cystic fibrosis patients - GSH-4Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-week inhalation treatment with glutathione in cystic fibrosis patients - GSH-4 Cystic fibrosis (CF) is the most common autosomal recessive lethal hereditary disorder in Caucasians. The majority of cystic fibrosis patients die as a result of progressive pulmonary disease. Airway inflammation, characterized by an excessive and persistent neutrophilic infiltration, is key for the pathogenesis of CF lung disease, and ultimately leads to lung destruction.Product Name: GSH (Glutathione)
Product Code: TAD 600
INN or Proposed INN: Glutathione
Other descriptive name: reduced glutathione
Mukoviszidose Institut gGmbH i. G.NULLNot RecruitingFemale: yes
Male: yes
160Germany